|
Brain Imaging in Alzheimer's Disease Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Brain Imaging in Alzheimer's Disease conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Brain Imaging in Alzheimer's Disease Clinical research trials and Brain Imaging in Alzheimer's Disease medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Brain Imaging in Alzheimer's Disease. Brain Imaging in Alzheimer's Disease Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Brain Imaging in Alzheimer's Disease clinical trial. Subjects often receive the most expert healthcare possible for their Brain Imaging in Alzheimer's Disease condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Brain Imaging in Alzheimer's Disease  Brain Imaging in Alzheimer's Disease
Brain Imaging in Alzheimer's Disease
For Condition: Alzheimer Disease
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to use brain imaging technology to examine the role of certain brain chemicals in individuals with Alzheimer's disease (AD) and in healthy volunteers. Cognitive dysfunction in people with AD is thought to arise from decreased chemical activity in specific parts of the brain. Decreases in alpha4beta2 nicotinic acetycholine receptors (nAChRs) have been found in the brains of people who died with AD; however, the status of this receptor system in living brains remains unclear. This study will use single photon emission computed tomography (SPECT) to study this receptor system in people with AD who have mild to moderate dementia and in healthy volunteers. In addition, this study will examine the relationship between cognitive dysfunction and nAChR deficits in the brains of individuals with AD. Participants with AD will have four clinic visits; healthy volunteers will have three visits. At Visit 1, participants will undergo a medical history, physical examination, and laboratory tests. Healthy volunteers will have a Mini-Mental State Examination (MMSE) cognitive function test. Participants with AD will have a MMSE and measurement of the severity of their dementia. During Visit 2, participants will undergo a magnetic resonance imaging (MRI) scan of the brain. At Visit 3, participants will undergo SPECT imaging. Only participants with AD will participate in Visit 4. During this visit, cognitive testing will be performed.
Details: Cognitive dysfunction in Alzheimer's disease (AD) patients are thought to arise in part from underlying losses of cholinergic input to cerebral cortex and hippocampus. Consistent marked decreases of alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are found in postmortem AD brains. However, knowledge of the in vivo status of this receptor system is limited due to the lack of suitable tracers for PET/SPECT imaging. We plan to use a new SPECT tracer, [123I]5-I-A-85380, which appears suitable for imaging the alpha4beta2 subtype of nAChRs, in order to delineate abnormalities of this receptor system in a "subgroup" of 20 mild to moderately demented AD patients against 20 age matched healthy controls, the "subgroup" being characterized by carrying the AD susceptibility Apolipoprotein E epsilon4 allele. In addition, we plan to examine the relationship between cognitive dysfunction and alpha4beta2 nAChr deficits in the cerebral cortex and hippocampus of these AD patients. This study represents our initial effort toward our long-term goal of understanding the role this important receptor system plays in the pathophysiological mechanisms and drug manipulation of AD.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA - ALZHEIMER'S DISEASE PATIENTS: All AD patients will meet NINCDS-ADRDA criteria for probable AD with age of onset between 50 and 65 years of age. The AD patients will be mild to moderately demented as assessed by the Mattis Dementia Rating Scale and Mini-Mental State Examination. In particular, the AD patients will be nonsmokers because of known effects of smoking on nAChRs. Patients will be characterized by their APOE genotype as nAChR changes might be different with differing doses of this allele. We will not exclude AD patients from participating while they are on AChe inhibitors. EXCLUSION CRITERIA - ALZHEIMER'S DISEASE PATIENTS: We will exclude patients who are on galanthamine (Reminyl). We will exclude patients on antidepressants and/or psychotropic drugs. INCLUSION CRITERIA - CONTROLS: Nonsmoking healthy individuals who satisfy the inclusion and exclusion criteria.
Total Enrollment: 40
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 020058; 02-M-0058
Study Start Date: June 3, 2002
Record last reviewed: October 15, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00039702
Other Alzheimer Disease Studies:
1. Electrophysiologic Measures of Treatment Response in Alzheimer Disease
2. Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
3. Study of Aripiprazole in the Treatment of Patients with Psychosis Associated with Dementia of the Alzheimer's Type
4. The Depression in Alzheimer's Disease Study (DIADS)
5. Multicenter Trial of Prednisone in Alzheimer's Disease
Related Studies:
Other Alzheimer Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Brain Imaging in Alzheimer's Disease
|
|
|
|
|
|
|
|
